<DOC>
	<DOCNO>NCT02455869</DOCNO>
	<brief_summary>The present study design single-centre , randomize , control clinical trial evaluate compare clinical efficacy two local drug delivery system contain 1 % ALN gel 1.2 % ATV gel treatment intrabony defect patient chronic periodontitis adjunct SRP .</brief_summary>
	<brief_title>Comparison Alendronate With Atorvastatin Chronic Periodontitis</brief_title>
	<detailed_description>Background : Alendronate Atorvastatin know inhibit osteoclastic bone resorption propose osteostimulative property cause osteoblast differentiation vivo vitro show increase matrix formation . The aim present study evaluate compare efficacy 1 % ALN 1.2 % ATV gel local drug delivery system adjunct scale root planning ( SRP ) treatment intrabony defect patient chronic periodontitis . Methods : A total 90 intrabony defect treat either1 % ALN , 1.2 % ATV placebo gel . Clinical parameter ( plaque index , modify sulcus bleed index , probe depth [ PD ] , clinical attachment level [ CAL ] ) record baseline , 3 , 6 9 month . Radiographic parameter intrabony defect depth ( IBD ) defect depth reduction ( DDR % ) calculate standardized radiograph use image analysis software 6 9 month .</detailed_description>
	<mesh_term>Periodontitis</mesh_term>
	<mesh_term>Chronic Periodontitis</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Alendronate</mesh_term>
	<criteria>Systemically healthy patient PDs ≥5mm CALs ≥4 6mm vertical bone loss ≥3 mm intraoral periapical radiograph history periodontal therapy use antibiotic precede 6 month include Patients know systemic disease ; know suspect allergy ALN/bisphosphonate group ATV/statin group ; systemic ALN/bisphosphonate therapy ATV/statin group ; aggressive periodontitis ; use tobacco form ; alcoholic ; immunocompromised patient ; pregnant lactating female exclude study</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>